The Biological Impact of Some Phosphonic and Phosphinic Acid Derivatives on Human Osteosarcoma
Authors:
- Zakzak KhaledZKZakzak Khaled
- Gheorghe IliaGheorghe Ilia
- Claudia WatzClaudia Watz
- Ioana MacașoiIMIoana Macașoi
- George DrăghiciGDGeorge Drăghici
- Vasile SimulescuVSVasile Simulescu
- Petru Eugen MerghesPMPetru Eugen Merghes
- Narcis Ion VaranNVNarcis Ion Varan
- Cristina Adriana DeheleanCristina Adriana Dehelean
- Lavinia VlaiaLVLavinia Vlaia
- Laurențiu SimaLaurențiu Sima
Open Access
- 15 May 2024
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (5) , 4815-4831
Abstract
Osteosarcoma malignancy currently represents a major health problem; therefore, the need for new therapy approaches is of great interest. In this regard, the current study aims to evaluate the anti-neoplastic potential of a newly developed phosphinic acid derivative (2-carboxyethylphenylphosphinic acid) and, subsequently, to outline its pharmaco-toxicological profile by employing two different in vitro human cell cultures (keratinocytes—HaCaT—and osteosarcoma SAOS-2 cells), employing different techniques (MTT assay, cell morphology assessment, LDH assay, Hoechst staining and RT-PCR). Additionally, the results obtained are compared with three commercially available phosphorus-containing compounds (P1, P2, P3). The results recorded for the newly developed compound (P4) revealed good biocompatibility (cell viability of 77%) when concentrations up to 5 mM were used on HaCaT cells for 24 h. Also, the HaCaT cultures showed no significant morphological alterations or gene modulation, thus achieving a biosafety profile even superior to some of the commercial products tested herein. Moreover, in terms of anti-osteosarcoma activity, 2-carboxyethylphenylphosphinic acid expressed promising activity on SAOS-2 monolayers, the cells showing viability of only 55%, as well as apoptosis features and important gene expression modulation, especially Bid downregulation. Therefore, the newly developed compound should be considered a promising candidate for further in vitro and in vivo research related to osteosarcoma therapy.Keywords
Funding Information
- “Victor Babes” University of Medicine and Pharmacy Timisoara
This publication has 44 references indexed in Scilit:
- Black phosphorus-incorporated novel Ti-12Mo-10Zr implant for multimodal treatment of osteosarcomaBioMetals, 2023
- Black phosphorus biomaterials for photo-controlled bone tissue engineeringComposites Part B: Engineering, 2022
- Eco-friendly phosphonic acid piperazine salt toward high-efficiency smoke suppression and flame retardancy for epoxy resinsJournal of Materials Science, 2021
- Phosphinic acids as building units in materials chemistryCoordination Chemistry Reviews, 2021
- Black Phosphorus: Degradation Mechanism, Passivation Method, and Application for In Situ Tissue RegenerationAdvanced Materials Interfaces, 2020
- 2D‐Black‐Phosphorus‐Reinforced 3D‐Printed Scaffolds:A Stepwise Countermeasure for OsteosarcomaAdvanced Materials, 2018
- Phosphate-independent utilization of phosphonoacetic acid as sole phosphorus source by a psychrophilic strain of Geomyces pannorum P15.Folia Microbiologica, 2014
- A Case for August Wilhelm Hofmann as the Originator of the Field of Organophosphorus ChemistryHeteroatom Chemistry, 2013
- Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53‐dependent pathwayJournal of Cellular Physiology, 2012
- Inorganic phosphate inhibits growth of human osteosarcoma U2OS cells via adenylate cyclase/cAMP pathwayJournal of Cellular Biochemistry, 2006